; The Pilot Project Program will provide funding for pilot projects and bridge funding as well as mentoring for junior investigators. We will provide a mechanism for investigators to apply for funding ($50,000-$100,000/annually) once a year. Total available funds will be $200,000/year. Dr. Shohet or Dr. Boisvert will review the applications and assign them to two scientific experts for peer-review following the NIH peer review format. After initial vetting arranged and coordinated by the Pilot Project Executive Committee the External Advisory Board will review the best applications to choose those that will be funded, based on merit and cardiovascular significance. All applicants will receive a summary statement. The objective will be to enhance the applicant's ability to reach research independence and national competitiveness. Three investigators that received modest pilot project funding during the last cycle have received (or are about to receive) substantial national funding for their work. These were the ONLY three projects funded during the last cycle as """"""""pilot projects"""""""" and all three scientists are now well on their way to stable positions in our Medical Center Our goal is that the Pilot Project-Bridging Program will stimulate and advance extramural funding of meritorious cardiovascular proposals.
Our specific aims encompass the two types of investigators we plan to support:
Specific Aim 1 : To allow new biomedical researchers to generate preliminary data for submission of grant applications related to cardiovascular pathology. We will create a rigorous and fair two step review process to select the most exciting science and the candidates most likely to succeed. We will provide mentoring to successful candidates based on the approach that worked well in the second cycle of the Cardiovascular COBRE.
Specific Aim 2 : To provide support to investigators with a formed application who require modest additional work to bring their grant to successful funding. We will support investigators with scored but unfunded R series grants of cardiovascular significance.
|Peterman, Karen; Withy, Kelley; Boulay, Rachel (2018) Validating Common Measures of Self-Efficacy and Career Attitudes within Informal Health Education for Middle and High School Students. CBE Life Sci Educ 17:ar26|
|Marciel, Michael P; Rose, Aaron H; Martinez, Verena et al. (2018) Calpain-2 inhibitor treatment preferentially reduces tumor progression for human colon cancer cells expressing highest levels of this enzyme. Cancer Med 7:175-183|
|Marciel, Michael P; Khadka, Vedbar S; Deng, Youpeng et al. (2018) Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis. Oncotarget 9:13407-13422|
|Lum, Corey J; Nakagawa, Kazuma; Shohet, Ralph V et al. (2017) The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target. Hawaii J Med Public Health 76:99-102|
|Dedinszki, Dóra; Szeri, Flóra; Kozák, Eszter et al. (2017) Oral administration of pyrophosphate inhibits connective tissue calcification. EMBO Mol Med 9:1463-1470|
|Pomozi, Viola; Brampton, Christopher; van de Wetering, Koen et al. (2017) Pyrophosphate Supplementation Prevents Chronic and Acute Calcification in ABCC6-Deficient Mice. Am J Pathol 187:1258-1272|
|Pomozi, Viola; Brampton, Christopher; Szeri, Flóra et al. (2017) Functional Rescue of ABCC6 Deficiency by 4-Phenylbutyrate Therapy Reduces Dystrophic Calcification in Abcc6-/- Mice. J Invest Dermatol 137:595-602|
|Norton, Robert L; Fredericks, Gregory J; Huang, Zhi et al. (2017) Selenoprotein K regulation of palmitoylation and calpain cleavage of ASAP2 is required for efficient Fc?R-mediated phagocytosis. J Leukoc Biol 101:439-448|
|Fong, Keith S K; Hufnagel, Robert B; Khadka, Vedbar S et al. (2016) A mutation in the tuft mouse disrupts TET1 activity and alters the expression of genes that are crucial for neural tube closure. Dis Model Mech 9:585-96|
|Chew, Glen M; Fujita, Tsuyoshi; Webb, Gabriela M et al. (2016) TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathog 12:e1005349|
Showing the most recent 10 out of 71 publications